Henlius Biotech

Since its founding in 2010, Fuhong Hanlin has built a full-industry-chain platform covering global R&D, clinical trials, registration, production, and commercialization. It has 10 approved products marketed in over 60 countries and regions.

Fuhong Hanlin has commercial agreements with international pharmaceutical companies including Abbott, Accord, Dr. Reddy’s, Eurofarma, KGbio, Organon, and Sandoz. Its licensed products reach over 100 countries or regions.

Fuhu Hanlin (2696.HK) is an international biopharmaceutical company specializing in oncology and autoimmune diseases, with 10 approved products globally and a full-value chain from R&D to commercialization.

Henlius presents positive findings from the **ASTRIDE U.S. study**, evaluating **serplulimab (Hetronifly®)**—an anti-PD-1 monoclonal antibody—combined with carboplatin and etoposide for **first-line treatment of extensive-stage small cell lung cancer (ES-SCLC)**. The randomized, open-label trial compares this combination to **atezolizumab plus chemotherapy**. Results were announced at the **European Society for Medical Oncology (ESMO) Congress 2026**.

Oct 2026PR NewswireNews article

Amberstone Biosciences partners with Henlius Biotech to develop pH-gated, tumor-activated T-cell engagers (TCEs) using Amberstone’s T-MATE™ platform. The collaboration focuses on preclinical applications targeting solid tumors. Henlius, a commercial-stage biopharmaceutical company, will leverage Amberstone’s proprietary technology to advance therapeutic development.

Sep 2026PR NewswireNews article

Henlius reports **27.3% year-over-year revenue growth to RMB 3.5882 billion** and **10.3% net profit growth to RMB 430.4 million** in its 2026 interim results. The company also highlights a **46.7% increase in non-IFRS profit to RMB 572.3 million**, driven by strong organic growth and earnings sustainability. Henlius continues advancing its global validation efforts while progressing toward its C-MNC (Comprehensive Multi-National Company) strategy.

Aug 2026PR NewswireNews article

Henlius Biotech grants Sandoz exclusive rights to commercialize up to 10 monoclonal antibody and antibody-drug conjugate (ADC) biosimilars outside China. The deal includes up to $322 million in payments. Sandoz will handle global distribution for these therapies, expanding Henlius’s market reach beyond Asia.

Aug 2026pharmexec.comNews article